<DOC>
<DOCNO>
EP-0000919
</DOCNO>
<TEXT>
<DATE>
19790307
</DATE>
<IPC-CLASSIFICATIONS>
C07K-14/435 C07K-14/655 <main>C07C-103/52</main> A61K-37/02 A61K-38/00 
</IPC-CLASSIFICATIONS>
<TITLE>
somatostatin analogs, process for their preparation and their use in pharmaceuticals.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc. <sep>
</APPLICANT>
<INVENTOR>
veber daniel frank<sep>veber, daniel frank<sep>veber, daniel frank290 batleson roadus-19002 ambler pennsylvaniaus<sep>veber, daniel frank <sep>veber, daniel frank290 batleson roadus-19002 ambler pennsylvaniaus<sep>
</INVENTOR>
<ABSTRACT>
somatostatin analogs having the structural formula:    wherein   r is h, cooh,   a is (asn)n, Î±-abu, pro, ala wherein n = 0 or 1,   b is phe, tyr,   c and d are independently thr, val,   e is ser, pro, ala, gly,   wherein at least one of a and e is pro and the ring formed  by the peptide backbone contains 35 to 38 atoms and pharmaceutically  acceptable non-toxic acid addition salts  thereof are prepared by the solid phase method.  these  peptides have the property of inhibiting the release of insulin,  glucagon and growth hormone and decreasing gastric  secretion in humans and animals.  the compounds are  particularly useful in the treatment of diabetes and gastric  ulcers.  
</ABSTRACT>
</TEXT>
</DOC>
